Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Hikal
Small Cap•2,061 Employees•IPO 1988
Current Price
₹181.59
-2.49 (-1.35%)Updated
Today's Range
₹180.92
₹186.67
₹181.59
52 Week Range
52W Low₹177.35
52W High₹456.75
₹181.59
Downside2.39%
Upside151.53%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹2,519.03 Cr
Market Cap
Total market value of companyP/E Ratio
249.41
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
2.60
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹0.82
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
1.25%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
9.85%
ROCE
Return on Capital Employed. >15% is goodNet Margin
0.59%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
1.42%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
4.29%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-6.49%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-539.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.61
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹102.38
Book Value
Net asset value per shareDividend Yield
0.68%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
68.80%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Hikal Ltd shows a strong promoter holding of 68.8%, indicating significant confidence in the company's future. This high promoter stake can also reduce the risk of hostile takeovers.
- •Despite recent quarterly profit decline, Hikal's long-term profitability is evident with a healthy operating profit margin (OPM) of 16.10%. This suggests underlying strength in its operations.
Weaknesses
6 points- •Hikal Ltd experienced a substantial 539% decrease in quarterly profits, reporting a net loss of ₹22.4 crore in the latest quarter, raising serious concerns about profitability.
- •The company's debt-to-equity ratio of 0.61 indicates a moderate level of debt. While not alarmingly high, it's a factor to monitor, especially given recent profit volatility.
Opportunities
4 points- •The broader Pharmaceuticals sector is experiencing robust growth, offering Hikal significant opportunities to expand its product portfolio and market reach.
- •Leveraging its presence in the pharma sector, Hikal can explore new product lines or therapeutic areas to diversify revenue streams and reduce dependency on existing products.
Threats
5 points- •Hikal faces intense competition from larger, more established players in the Pharmaceuticals sector, which could pressure margins and hinder market share growth.
- •The highly regulated nature of the pharmaceutical industry means changes in policies or compliance requirements could significantly impact operations and profitability.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹196.70 | +₹15.11 | +8.32% |
| R3 | ₹190.95 | +₹9.36 | +5.15% |
| R2 | ₹188.81 | +₹7.22 | +3.98% |
| R1 | ₹185.20 | +₹3.61 | +1.99% |
| PIVOT | ₹183.06 | 1.47 | 0.81% |
| CURRENT | ₹181.59 | - | - |
| S1 | ₹167.95 | -₹13.64 | -7.51% |
| S2 | ₹173.70 | -₹7.89 | -4.34% |
| S3 | ₹177.31 | -₹4.28 | -2.36% |
| S4 | ₹179.45 | -₹2.14 | -1.18% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-92.4% vs avg
2.01L
(06 Mar 2026)Delivery %+21.4% vs avg
54.7%
(06 Mar 2026)Avg Volume (20D)20-day average
2.64M
(06 Feb - 06 Mar)Avg Delivery %Trend ↑
33.3%
(06 Feb - 06 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Solara Active Pharma Sciences Ltd
178.00 %
Highest Dividend Yield
RPG Life Sciences Ltd
1.22 %
Peer Comparison
| Company Name |
|---|
 Aarti Drugs Ltd |
 Amrutanjan Health Care Ltd |
 Bliss GVS Pharma Ltd |
 Gufic BioSciences Ltd |
 Indoco Remedies Ltd |
 IOL Chemicals & Pharmaceuticals Ltd |
 Morepen Laboratories Ltd |
 Orchid Pharma Ltd |
 RPG Life Sciences Ltd |
 Senores Pharmaceuticals Ltd |
 SMS Pharmaceuticals Ltd |
 Solara Active Pharma Sciences Ltd |
 Sun Pharmaceutical Industries Ltd |
 Unichem Laboratories Ltd |
About
Hikal Ltd
Hikal Limited is a global manufacturer and supplier of a diverse range of chemical products, primarily serving the pharmaceutical, animal health, crop protection, and specialty chemicals industries. Their operations span across multiple continents, including India, the United States, Canada, Europe, and Southeast Asia, showcasing a significant international presence and market reach.
The company's business is structured into two key segments: Pharmaceuticals and Crop Protection. The Pharmaceuticals segment focuses on the production of Active Pharmaceutical Ingredients (APIs), which are crucial components in the creation of various medications. This segment contributes significantly to the global pharmaceutical supply chain by providing essential building blocks for numerous drugs.
The Crop Protection segment manufactures a broad spectrum of pesticides and herbicides, including notable products such as diuron tech, temephos tech, and several others. These products cater to the agricultural sector, aiding in crop protection and yield enhancement. The breadth of their offerings within this segment establishes Hikal as a key player in the agrochemical industry.
Beyond its core manufacturing activities, Hikal also provides comprehensive contract research and custom synthesis services. This allows them to offer tailored solutions for clients requiring specific chemical intermediates or active ingredients, strengthening their position as a versatile partner for various industries. They further expand their services to include custom manufacturing, catering to clients' specialized needs.
Hikal's product portfolio extends beyond APIs and agrochemicals. They also offer a range of human and animal health products, including a variety of medications addressing different therapeutic areas. Additionally, they supply specialty biocides and antimicrobial actives, along with additives for diverse industries such as leather, paint, paper, water treatment, personal care, building materials, and textiles, demonstrating the breadth and versatility of their chemical manufacturing capabilities.
COMPANY FACTS - HIKAL
Registered Address
Great Eastern Chambers, Sector 11, CBD-Belapur
Navi Mumbai
MAHARASHTRA
IN
Tel: 912230973100
Website:https://www.hikal.com/
Investor Relations:http://hikal.com/documents/annual-reports
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 2,061
IPO Date: 08/07/1988
MANAGEMENT - HIKAL
Mr. Jai Hiremath
Executive Chairman of the Board
Mr. Sameer Hiremath
Chief Executive Officer, Managing Director, Executive Director
Mr. Kuldeep Jain
Chief Financial Officer
Mr. Rajasekhar Reddy
Compliance Officer, Company Secretary
Mr. Sarangan Suresh
Additional Executive Director
Mrs. Sugandha Hiremath
Non-Executive Director
Mr. Amit Kalyani
Non-Executive Director
Mr. Shrikrishna Adivarekar
Independent Non-Executive Director
Mr. Berjis Desai
Non-Executive Independent Director
Mr. Ravi Kapoor
Additional Non-Executive Independent Director
Ms. Shivani Sachdeva
Independent Non-Executive Director
Ms. Ranjana Salgaocar
Additional Non-Executive Independent Director
Investor Questions Answered
Hikal Ltd (HIKAL) Stock FAQs
Get answers to the most common questions about Hikal Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Hikal Ltd (HIKAL) is ₹181.59. Today, the stock has declined by ₹2.49 (1.35%), trading in a range of ₹180.92 to ₹186.67. The stock opened at ₹184.88 with a trading volume of 2,00,761 shares.
Hikal Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,519.03 crores, P/E ratio of 249.41, ROE of 1.25%, and ROCE of 9.85%. The dividend yield stands at 0.68%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Hikal Ltd (HIKAL) is ₹456.75, while the 52-week low is ₹177.35. Currently trading at ₹181.59, the stock is 1.5% away from its 52-week low and 60.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Hikal Ltd stock at ₹181.59 depends on multiple factors. The stock is currently trading with a P/E ratio of 249.41 and P/B ratio of N/A. Today's performance shows a loss of 1.35%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Hikal Ltd offers a dividend yield of 0.68%, which means for every ₹100 invested at the current price of ₹181.59, you can expect to receive approximately ₹0.68 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Hikal Ltd's key financial metrics include: P/E Ratio: 249.41, P/B Ratio: N/A, ROE: 1.25%, ROCE: 9.85%, Dividend Yield: 0.68%, EPS: ₹0.82, Book Value: ₹102.38, Debt-to-Equity: 0.61, and Current Ratio: N/A. The company's market cap stands at ₹2,519.03 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Hikal Ltd stock opened at ₹184.88 and is currently trading at ₹181.59, showing a decline of ₹2.49 (1.35%). The intraday high is ₹186.67 and low is ₹180.92. The trading volume stands at 2,00,761 shares, indicating moderate market participation today.
Hikal Ltd has a Price-to-Earnings (P/E) ratio of 249.41, which means investors are willing to pay ₹249.41 for every ₹1 of earnings. With an EPS of ₹0.82, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Hikal Ltd has a market capitalization of ₹2,519.03 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹181.59) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Hikal Ltd has a book value of ₹102.38 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹181.59, which is 77.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Hikal Ltd has a Return on Equity (ROE) of 1.25% and Return on Capital Employed (ROCE) of 9.85%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Hikal Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Hikal Ltd has a debt-to-equity ratio of 0.61, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Hikal Ltd has an Earnings Per Share (EPS) of ₹0.82, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹181.59 and P/E ratio of 249.41, investors are paying 249.41 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Hikal Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Hikal Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Hikal Ltd stock, consider: 1) Fundamental Analysis - Review P/E (249.41), ROE (1.25%), debt-to-equity (0.61), and growth rates. 2) Technical Analysis - Check 52-week range (₹177.35 - ₹456.75), moving averages, and chart patterns. 3) Valuation - Compare current price (₹181.59) with book value (₹102.38) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Hikal Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹181.59 is 8980x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Hikal Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹177.35 - ₹456.75). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.61 indicates leverage. 4) Liquidity Risk - Based on trading volume of 2,00,761 shares. 5) Valuation Risk - P/E of 249.41 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Hikal Ltd operates in the industry with key metrics: P/E ratio of 249.41, ROE of 1.25%, market cap of ₹2,519.03 crores, and dividend yield of 0.68%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.61), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Hikal Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹181.59, with a 52-week range of ₹177.35 to ₹456.75. Based on fundamentals like P/E (249.41), ROE (1.25%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Hikal Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹181.59. 2) Fundamental Deterioration - Declining ROE (currently 1.25%), increasing debt (D/E: 0.61), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Hikal Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.68%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu